- Home
- IFRX vs IOBT Comparison
IFRX vs IOBT Comparison
Compare IFRX & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- IOBT
- Stock Information
- Founded
- IFRX 2007
- IOBT 2014
- Country
- IFRX Germany
- IOBT Denmark
- Employees
- IFRX N/A
- IOBT N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- IOBT Health Care
- Exchange
- IFRX Nasdaq
- IOBT Nasdaq
- Market Cap
- IFRX 65.8M
- IOBT 56.5M
- IPO Year
- IFRX 2017
- IOBT 2021
- Fundamental
- Price
- IFRX $1.30
- IOBT $0.94
- Analyst Decision
- IFRX Strong Buy
- IOBT Strong Buy
- Analyst Count
- IFRX 2
- IOBT 3
- Target Price
- IFRX $9.00
- IOBT $9.33
- AVG Volume (30 Days)
- IFRX 322.6K
- IOBT 145.4K
- Earning Date
- IFRX 05-07-2025
- IOBT 05-13-2025
- Dividend Yield
- IFRX N/A
- IOBT N/A
- EPS Growth
- IFRX N/A
- IOBT N/A
- EPS
- IFRX N/A
- IOBT N/A
- Revenue
- IFRX $171,642.00
- IOBT N/A
- Revenue This Year
- IFRX $106.72
- IOBT N/A
- Revenue Next Year
- IFRX $66.89
- IOBT N/A
- P/E Ratio
- IFRX N/A
- IOBT N/A
- Revenue Growth
- IFRX 162.79
- IOBT N/A
- 52 Week Low
- IFRX $0.82
- IOBT $0.66
- 52 Week High
- IFRX $2.82
- IOBT $1.79
- Technical
- Relative Strength Index (RSI)
- IFRX 58.32
- IOBT 50.60
- Support Level
- IFRX $0.82
- IOBT $0.85
- Resistance Level
- IFRX $1.12
- IOBT $0.97
- Average True Range (ATR)
- IFRX 0.13
- IOBT 0.08
- MACD
- IFRX 0.06
- IOBT 0.00
- Stochastic Oscillator
- IFRX 90.49
- IOBT 64.71
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.